Please use this identifier to cite or link to this item:
https://doi.org/10.18632/oncotarget.227
Title: | A robust approach to enhance tumor-selective accumulation of nanoparticles | Authors: | Qiao, Y Huang, X Nimmagadda, S Bai, R Staedtke, V Foss, C.A Cheong, I Holdhoff, M Kato, Y Pomper, M.G Riggins, G.J Kinzler, K.W Diaz Jr Vogelstein, B Zhou, S |
Keywords: | doxorubicin nanoparticle recombinant tumor necrosis factor alpha antineoplastic agent drug carrier animal cell animal experiment animal model animal tissue article bacterial infection cancer survival colorectal carcinoma controlled study drug accumulation drug delivery system drug penetration drug retention drug targeting female isotope labeling mouse nonhuman radioactivity animal chemistry disease model human metabolism neoplasm vascularization Animals Antineoplastic Agents Disease Models, Animal Drug Carriers Humans Mice Nanoparticles Neoplasms |
Issue Date: | 2011 | Publisher: | Impact Journals | Citation: | Qiao, Y, Huang, X, Nimmagadda, S, Bai, R, Staedtke, V, Foss, C.A, Cheong, I, Holdhoff, M, Kato, Y, Pomper, M.G, Riggins, G.J, Kinzler, K.W, Diaz Jr, Vogelstein, B, Zhou, S (2011). A robust approach to enhance tumor-selective accumulation of nanoparticles. Oncotarget 2 (43497) : 59-68. ScholarBank@NUS Repository. https://doi.org/10.18632/oncotarget.227 | Rights: | Attribution 4.0 International | Abstract: | While nanoparticles have shown great promise as drug carriers in cancer therapy, their effectiveness is critically dependent on the structural characteristics of the tumor vasculature. Here we demonstrate that several agents capable of inducing vascular responses akin to those observed in inflammatory processes enhance the accumulation of nanoparticles in tumors. The vascular-active agents tested in this study included a bacterium, a pro-inflammatory cytokine, and microtubuledestabilizing drugs. Using radiolabeled nanoparticles, we show that such agents can increase the tumor to blood ratio of radioactivity by more than 20-fold compared to nanoparticles alone. Moreover, vascular-active agents dramatically improved the therapeutic effect of nanoparticles containing radioactive isotopes or chemotherapeutic agents. This resulted in cures of animals with subcutaneous tumors and significantly prolonged the survival of animals with orthotopic brain tumors. In principle, a variety of vascular-active agents and macromolecular anticancer formulations can be combined, which makes this approach broadly applicable and particularly suited for the treatment of patients who have failed standard therapies. © Qiao et al. | Source Title: | Oncotarget | URI: | https://scholarbank.nus.edu.sg/handle/10635/178185 | ISSN: | 1949-2553 | DOI: | 10.18632/oncotarget.227 | Rights: | Attribution 4.0 International |
Appears in Collections: | Staff Publications Elements |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_18632_oncotarget_227.pdf | 10.96 MB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License